Piritrexim
Term · Oncology and biomedicine · MLC-T-ONC-006698
A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called folate antagonists.
A synthetic antifolate agent with antiparasitic, antipsoriatic and antitumor properties. Piritrexim inhibits the enzyme dihydrofolate reductase enzyme, thereby disrupting folate metabolism and DNA synthesis and cell division.
| Identifier | MLC-T-ONC-006698 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | Piritrexim Isethionate |
| References | NCI Dictionary of Cancer Terms; National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-006698",
"term": "Piritrexim",
"field": "Oncology and biomedicine",
"definitions": [
"A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called folate antagonists.",
"A synthetic antifolate agent with antiparasitic, antipsoriatic and antitumor properties. Piritrexim inhibits the enzyme dihydrofolate reductase enzyme, thereby disrupting folate metabolism and DNA synthesis and cell division."
],
"synonyms": [
"Piritrexim Isethionate"
],
"references": [
"NCI Dictionary of Cancer Terms",
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/piritrexim/"
}
Record 13,275 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.